Qual o benefício do inibidor da anidrase carbônica como quarta droga no paciente com glaucoma primário?

• Autor(a) principal: Juncal, Verena Ribeiro [UNIFESP]
• Data de Publicação: 2017
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=4122483; https://repositorio.unifesp.br/handle/11600/47611
• topic: Primary glaucoma; Carbonic anhydrase inhibitor therapy; Glaucoma primário; Inibidor da anidrase carbônica terapia

OBJECTIVE: To evaluate the efficacy of the carbonic anhydrase inhibitor as the fourth drug In the intraocular pressure (IOP) of patients with primary glaucoma. METHODS: This was a prospective study involving 25 patients Accompanied at the Federal University of São Paulo with primary glaucoma and Treated concomitantly with the following topical medications: Prostaglandin, beta-blocker, alpha-adrenergic agonist and anhydrase inhibitor Carbonic acid. The patients were recruited between August and November Initially underwent the complete ophthalmic examination and the IOP was measured at 8:00 a.m., 10:00 a.m. and 12:00 p.m. Then the carbonic anhydrase inhibitor was suspended For 15 days and, after this period, the patients were reassessed for measurement Of IOP. RESULTS: The majority of the patients were female, white, with a Mean age of 66.4 ± 9.7 years. Suspension of the fourth medication had a Was statistically significant at peak IOP (1.20 mmHg increase, p <0.01) and Mean IOP (1.23mmHg increase, p <0.01), but did not significantly interfere In its morning fluctuation (p = 0.83). After discontinuation of the fourth drug, the IOP Increased ? 2 mmHg in 32% of the patients and there was a significant increase in IOP (Defined as ?20%) in only 5 patients (20%). Advanced age (greater than 60 years) was the only factor among those analyzed that showed an association With IOP variation after discontinuation of the fourth drug (R2 = 0.19; P = 0.03). CONCLUSIONS: Removal of the fourth medication had a statistically significant Significant difference in IOP control. However, this increase does not seem to have been clinically meaningful, since not only the mean variation was small (<1.3 MmHg), but also the majority of the patients (80%) presented no increase Significant difference in IOP (defined as IOP variation ?20%). Google Tradutor para empresas:Google Toolkit de tradução para appsTradutor de sitesGlobal Market Finder